Difference between revisions of "Dacomitinib (Vizimpro)"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *9/27/2018: Initial approval for the first-line treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] with [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[#Biomarkers_Structural Variant|deletion]] or [[Biomarkers#L858R|exon 21 L858R substitution]] mutations. | + | *9/27/2018: Initial approval for the first-line treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] with [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[#Biomarkers_Structural Variant|deletion]] or [[Biomarkers#L858R|exon 21 L858R substitution]] mutations. ''(Based on ARCHER 1050)'' |
== Patient Drug Information== | == Patient Drug Information== | ||
Revision as of 22:12, 4 May 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells.
Diseases for which it is approved
History of changes in FDA indication
- 9/27/2018: Initial approval for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations. (Based on ARCHER 1050)
Patient Drug Information
Also known as
- Code name: PF-00299804
- Brand name: Vizimpro